Trdn-as directs m6A-dependent transcriptional termination for accurate triadin isoform switching, preventing aberrant dyads and cardiomyopathy.
Summary
This mechanistic study demonstrates that the lncRNA TRDN-AS acts in cis to regulate RNA polymerase II stalling and m6A-dependent transcriptional termination of the cardiac TRDN transcript. Loss of TRDN-AS or METTL3-mediated regulation produces an aberrant triadin isoform, disrupts calcium-release-complex interactions and dyad structure, prolongs the QT interval, and causes dilated cardiomyopathy in mice and humans.
Key Findings
- Reduced or abrogated TRDN-AS causes switching from the cardiac TRDN/TRISK32 isoform to the skeletal-muscle TRDN/TRISK95 isoform.
- TRDN-AS transcription in cis promotes RNA polymerase II stalling, while METTL3-dependent m6A regulation supports transcriptional termination and proximal polyadenylation.
- Aberrant triadin isoform switching alters calcium-release-complex interactomes and dyad architecture, producing abnormal calcium handling and QT prolongation.
- TRDN-AS disruption is associated with dilated cardiomyopathy in experimental models and human cardiomyopathy.
Clinical Implications
TRDN-AS-dependent isoform regulation may become a biomarker or therapeutic target for selected cardiomyopathies associated with calcium-handling abnormalities, QT prolongation, or dilated remodeling. Clinical translation will require validation in larger patient cohorts and development of safe methods to modulate lncRNA or m6A-dependent RNA processing.
Why It Matters
The paper provides a novel molecular explanation linking RNA processing to excitation-contraction coupling, electrical instability, and cardiomyopathy. Its cross-species validation and identification of a potentially targetable lncRNA–METTL3 pathway substantially advance mechanistic understanding beyond descriptive genetic associations.
Limitations
- The abstract does not provide the number of human samples, experimental replicates, or detailed effect sizes for all phenotypes.
- Causal translation to common human cardiomyopathy subtypes and the prevalence of pathogenic TRDN-AS dysregulation remain to be established.
- Therapeutic modulation of a lncRNA or METTL3 pathway may have tissue-specific and off-target effects that are not resolved by the current study.
Future Directions
Future work should define the prevalence of TRDN-AS and TRDN isoform abnormalities across inherited and acquired cardiomyopathies, establish genotype-phenotype relationships, and test targeted RNA-based or epitranscriptomic interventions in long-term in vivo models. Patient-derived cardiomyocytes could support precision-medicine approaches.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- III - A rigorous translational mechanistic study using human disease material and experimental cellular and animal models, without a clinical intervention trial.
- Study Design
- OTHER